Comparison of Paclitaxel-, Sirolimus-, and Zotarolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction and Metabolic Syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Min Goo | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.contributor.author | Ahn, Youngkeun | - |
dc.contributor.author | Cho, Jeong Gwan | - |
dc.contributor.author | Park, Jong Chun | - |
dc.contributor.author | Kang, Jung Chaee | - |
dc.contributor.author | Chae, Shung Chull | - |
dc.contributor.author | Hur, Seung Ho | - |
dc.contributor.author | Hong, Taek Jong | - |
dc.contributor.author | Kim, Young Jo | - |
dc.contributor.author | Seong, In Whan | - |
dc.contributor.author | Chae, Jei Keon | - |
dc.contributor.author | Rhew, Jay Young | - |
dc.contributor.author | Chae, In Ho | - |
dc.contributor.author | Cho, Myeong Chan | - |
dc.contributor.author | Bae, Jang Ho | - |
dc.contributor.author | Rha, Seung Woon | - |
dc.contributor.author | Kim, Chong Jin | - |
dc.contributor.author | Choi, Donghoon | - |
dc.contributor.author | Jang, Yang Soo | - |
dc.contributor.author | Yoon, Junghan | - |
dc.contributor.author | Chung, Wook Sung | - |
dc.contributor.author | Seung, Ki Bae | - |
dc.contributor.author | Park, Seung Jung | - |
dc.date.accessioned | 2021-09-07T08:48:14Z | - |
dc.date.available | 2021-09-07T08:48:14Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2011-09 | - |
dc.identifier.issn | 1346-9843 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111672 | - |
dc.description.abstract | Background: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS). Methods and Results: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005-December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (all-cause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9%, 9.1%, and 11.0%, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3% in PES group, 0.4% in SES group, and 0.4% in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9% in PES group, 1.0% in SES group, and 1.3% in ZES group, respectively, P=0.448). Conclusions: Implantation of SES, PES, and ZES in MS patients with STEMI undergoing primary PCI provided comparable clinical outcomes in patients enrolled in KAMIR. (Circ J 2011; 75: 2120-2127) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | JAPANESE CIRCULATION SOC | - |
dc.subject | CORONARY-ARTERY-DISEASE | - |
dc.subject | BARE-METAL STENTS | - |
dc.subject | BALLOON ANGIOPLASTY | - |
dc.subject | RANDOMIZED-TRIALS | - |
dc.subject | UNCOATED STENTS | - |
dc.subject | METAANALYSIS | - |
dc.subject | RISK | - |
dc.subject | IMPLANTATION | - |
dc.subject | EFFICACY | - |
dc.subject | THERAPY | - |
dc.title | Comparison of Paclitaxel-, Sirolimus-, and Zotarolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction and Metabolic Syndrome | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung Woon | - |
dc.identifier.doi | 10.1253/circj.CJ-11-0263 | - |
dc.identifier.scopusid | 2-s2.0-80052157400 | - |
dc.identifier.wosid | 000294507300018 | - |
dc.identifier.bibliographicCitation | CIRCULATION JOURNAL, v.75, no.9, pp.2120 - 2127 | - |
dc.relation.isPartOf | CIRCULATION JOURNAL | - |
dc.citation.title | CIRCULATION JOURNAL | - |
dc.citation.volume | 75 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 2120 | - |
dc.citation.endPage | 2127 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | CORONARY-ARTERY-DISEASE | - |
dc.subject.keywordPlus | BARE-METAL STENTS | - |
dc.subject.keywordPlus | BALLOON ANGIOPLASTY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIALS | - |
dc.subject.keywordPlus | UNCOATED STENTS | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | IMPLANTATION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Drug-eluting stent | - |
dc.subject.keywordAuthor | Metabolic syndrome | - |
dc.subject.keywordAuthor | Myocardial infarction | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.